Trial Profile
A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between BR1010 and Co-administration of BR1010-1 and BR1010-2 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2019
Price :
$35
*
At a glance
- Drugs Amlodipine/fimasartan/hydrochlorothiazide (Primary) ; Amlodipine/fimasartan; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 08 Jan 2019 Status changed from not yet recruiting to completed.
- 23 Aug 2018 New trial record